- Home
- NOTV vs RNXT Comparison
NOTV vs RNXT Comparison
Compare NOTV & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- RNXT
- Stock Information
- Founded
- NOTV 1974
- RNXT 2012
- Country
- NOTV United States
- RNXT United States
- Employees
- NOTV N/A
- RNXT N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NOTV Health Care
- RNXT Health Care
- Exchange
- NOTV Nasdaq
- RNXT Nasdaq
- Market Cap
- NOTV 46.7M
- RNXT 40.7M
- IPO Year
- NOTV 1997
- RNXT 2021
- Fundamental
- Price
- NOTV $1.43
- RNXT $1.29
- Analyst Decision
- NOTV Strong Buy
- RNXT Strong Buy
- Analyst Count
- NOTV 1
- RNXT 2
- Target Price
- NOTV $5.00
- RNXT $7.50
- AVG Volume (30 Days)
- NOTV 342.4K
- RNXT 724.7K
- Earning Date
- NOTV 12-02-2025
- RNXT 11-12-2025
- Dividend Yield
- NOTV N/A
- RNXT N/A
- EPS Growth
- NOTV N/A
- RNXT N/A
- EPS
- NOTV N/A
- RNXT N/A
- Revenue
- NOTV $505,299,000.00
- RNXT $662,000.00
- Revenue This Year
- NOTV $5.64
- RNXT $2,895.35
- Revenue Next Year
- NOTV $5.16
- RNXT $313.04
- P/E Ratio
- NOTV N/A
- RNXT N/A
- Revenue Growth
- NOTV 0.85
- RNXT N/A
- 52 Week Low
- NOTV $1.15
- RNXT $0.75
- 52 Week High
- NOTV $6.48
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- NOTV 44.87
- RNXT 54.48
- Support Level
- NOTV $1.25
- RNXT $1.06
- Resistance Level
- NOTV $1.55
- RNXT $1.15
- Average True Range (ATR)
- NOTV 0.12
- RNXT 0.10
- MACD
- NOTV 0.01
- RNXT -0.02
- Stochastic Oscillator
- NOTV 43.24
- RNXT 56.16
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.